THERAPY DOSSIER · th-315bc600cf13

Anti-B7-1 (anti-CD80) antibody

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00384150 ↗PHASE3terminated

Retreatment Study of Galiximab in Combination With Rituximab for Relapsed Follicular NHL

Lymphoma, Non-Hodgkin's

Enrolment: 16 · Results not recorded

NCT00363636 ↗PHASE3terminated

Galiximab + Rituximab vs Rituximab + Placebo for Relapsed/Refractory Follicular NHL

Lymphoma, Non-Hodgkin's

Enrolment: 340 · Results not recorded

NCT00117975 ↗PHASE2completed

Extended Induction Galiximab (Anti-CD80 mAb) Plus Rituximab in Untreated Follicular NHL

Lymphoma

Enrolment: 62 · Results not recorded

NCT03851614 ↗PHASE2active not recruiting

Basket Combination Study of DDR, Angiogenesis and PD-L1 Inhibitors in Advanced Solid Tumors

Colorectal Cancer · Pancreatic Adenocarcinoma · Leiomyosarcoma

Enrolment: 90 · Results not recorded

NCT00516217 ↗PHASE2completed

Phase II Study of Galiximab (Anti-CD80) for Relapsed/Refractory Hodgkin Lymphoma

Lymphoma

Enrolment: 30 · Results not recorded

NCT02374242 ↗PHASE2active not recruiting

Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Melanoma Brain Metastases

Melanoma · Brain Metastases

Enrolment: 76 · Results not recorded

NCT00575068 ↗PHASE1/PHASE2completed

Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) for Relapsed/Refractory Follicular Lymphoma

Non-Hodgkin's Lymphoma

Enrolment: 42 · Results not recorded

NCT06163820 ↗PHASE1/PHASE2recruiting

Bevacizumab and Immune Checkpoint Inhibitors Plus Hypofractionated SRT for Melanoma Brain Metastases

Melanoma Brain Metastases

Enrolment: 46 · Results not recorded

NCT00048555 ↗PHASE1/PHASE2completed

Phase I/II Trial of IDEC-114 (Anti-CD80 mAb) With Rituxan for Relapsed/Refractory Follicular Lymphoma

Non-Hodgkin's Lymphoma

Enrolment: 90 · Results not recorded

NCT00651443 ↗PHASE1terminated

Phase I Study to Evaluate Mechanism of Action of Galiximab in Untreated Follicular NHL

Lymphoma, Non-Hodgkin's

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26980009 ↗2016Mixed findings

Blocking B7-1/CD28 Pathway Diminished Long-Range Brain Damage by Regulating the Immune and Inflammatory Responses in a Mouse Model of Intracerebral Hemorrhage.

MouseOtherICRMaleInner canthus venous plexus injection10 min and 24 h after intracerebral haemorrhage

Model: Experimental intracerebral haemorrhage

Anti-B7-1 antibody lowered immune function, reduced the interferon gamma to interleukin-4 ratio, shortened water maze latency on days 18 and 20, and reduced body weight on day 3, which the authors interpret as reduced long-range brain damage through reversal of immune imbalance.

Extraction: extract · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.

Loading the evidence…